Published in Cancer Immun on February 06, 2007
Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine (2008) 1.28
Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther (2008) 1.24
Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs (2010) 1.18
Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer (2008) 1.06
Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine (2008) 1.01
Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice. Mol Ther (2011) 1.00
Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc (2010) 0.99
Immunologic treatments for precancerous lesions and uterine cervical cancer. J Exp Clin Cancer Res (2014) 0.96
Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs (2012) 0.96
Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev (2008) 0.96
Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy. Front Cell Infect Microbiol (2014) 0.96
Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors. Immunol Res (2008) 0.94
Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy. Clin Vaccine Immunol (2008) 0.92
New Approaches to Immunotherapy for HPV Associated Cancers. Cancers (Basel) (2011) 0.89
Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors. Clin Cancer Res (2009) 0.88
Episomal expression of truncated listeriolysin O in LmddA-LLO-E7 vaccine enhances antitumor efficacy by preferentially inducing expansions of CD4+FoxP3- and CD8+ T cells. Cancer Immunol Res (2014) 0.84
Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunization. Viral Immunol (2009) 0.83
Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy (2014) 0.81
Progress and challenges in the vaccine-based treatment of head and neck cancers. J Exp Clin Cancer Res (2009) 0.81
Listeriolysin O as a strong immunogenic molecule for the development of new anti-tumor vaccines. Hum Vaccin Immunother (2013) 0.80
Effect of human papillomavirus infection on the immune system and its role in the course of cervical cancer. Oncol Lett (2015) 0.79
Antiangiogenesis immunotherapy induces epitope spreading to Her-2/neu resulting in breast tumor immunoediting. Breast Cancer (Dove Med Press) (2009) 0.78
Listeria-derived ActA is an effective adjuvant for primary and metastatic tumor immunotherapy. Cancer Immunol Immunother (2010) 0.77
In vivo modulation of avidity in highly sensitive CD8(+) effector T cells following viral infection. Viral Immunol (2013) 0.75
Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy. Gynecol Oncol Res Pract (2017) 0.75
Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science (1986) 15.84
Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst (2000) 14.43
Projection of an immunological self shadow within the thymus by the aire protein. Science (2002) 12.15
PEST sequences and regulation by proteolysis. Trends Biochem Sci (1996) 8.90
Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol (2001) 7.30
Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res (1996) 6.03
Aire regulates negative selection of organ-specific T cells. Nat Immunol (2003) 5.85
The cellular mechanism of Aire control of T cell tolerance. Immunity (2005) 4.74
Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol (1993) 3.73
Heterologous introns can enhance expression of transgenes in mice. Proc Natl Acad Sci U S A (1991) 3.34
Central tolerance to tissue-specific antigens mediated by direct and indirect antigen presentation. J Exp Med (2004) 3.30
Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med (2005) 3.22
A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity. Science (2000) 2.51
Gene dosage--limiting role of Aire in thymic expression, clonal deletion, and organ-specific autoimmunity. J Exp Med (2004) 2.43
Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A (2004) 2.27
Genital human papillomavirus infection. Proc Natl Acad Sci U S A (1994) 2.12
Analysis of thymic stromal cell populations using flow cytometry. J Immunol Methods (2002) 2.11
Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer (2002) 1.92
A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nat Med (1995) 1.78
Epidermal cancer associated with expression of human papillomavirus type 16 E6 and E7 oncogenes in the skin of transgenic mice. Proc Natl Acad Sci U S A (1993) 1.48
Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J Immunol (2005) 1.33
The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine. J Immunol (2005) 1.31
Peptide requirement for CTL activation reflects the sensitivity to CD3 engagement: correlation with CD8alphabeta versus CD8alphaalpha expression. J Immunol (2001) 1.30
Synergy between tumor immunotherapy and antiangiogenic therapy. Blood (2003) 1.23
Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol Rev (2002) 1.20
Targeted expression of the E6 and E7 oncogenes of human papillomavirus type 16 in the epidermis of transgenic mice elicits generalized epidermal hyperplasia involving autocrine factors. Mol Cell Biol (1994) 1.14
Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7. Cancer Res (2004) 1.13
Identification of tumour-associated T-cell epitopes for vaccine development. Nat Rev Cancer (2002) 1.11
The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity. Eur J Immunol (2004) 1.08
Rapid and accurate determination of zygosity in transgenic animals by real-time quantitative PCR. Transgenic Res (2002) 1.06
Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16. J Virol (1997) 1.01
Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine. Arch Otolaryngol Head Neck Surg (2004) 1.00
Split tolerance to a viral antigen expressed in thymic epithelium and keratinocytes. Eur J Immunol (1998) 0.97
Tissue-specific expression and methylation of a thyroglobulin-chloramphenicol acetyltransferase fusion gene in transgenic mice. Proc Natl Acad Sci U S A (1990) 0.95
Mice expressing the E7 oncogene of HPV16 in epithelium show central tolerance, and evidence of peripheral anergising tolerance, to E7-encoded cytotoxic T-lymphocyte epitopes. Virology (1998) 0.93
What is needed for effective antitumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV-associated tumors. Cancer Immunol Immunother (2005) 0.89
Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Gene Ther (2005) 0.89
Nonspecific down-regulation of CD8+ T-cell responses in mice expressing human papillomavirus type 16 E7 oncoprotein from the keratin-14 promoter. J Virol (2001) 0.87
Differentiated carcinomas develop as a consequence of the thyroid specific expression of a thyroglobulin-human papillomavirus type 16 E7 transgene. Oncogene (1995) 0.86
Antigen recognition and T-cell biology. Cancer Treat Res (2005) 0.81
Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. Nature (2003) 5.14
Analysis of 16S libraries of mouse gastrointestinal microflora reveals a large new group of mouse intestinal bacteria. Microbiology (2002) 2.71
A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors. Clin Cancer Res (2009) 1.72
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother (2007) 1.70
Enteric salmonella infection inhibits Paneth cell antimicrobial peptide expression. Infect Immun (2003) 1.69
High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action. Cancer Res (2009) 1.39
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol (2007) 1.38
Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia. Blood (2005) 1.34
Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J Immunol (2005) 1.33
Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. PLoS One (2009) 1.19
Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7. Cancer Res (2004) 1.13
Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res (2008) 1.11
Genome-wide profiling of oral squamous cell carcinoma by array-based comparative genomic hybridization. Laryngoscope (2006) 1.08
CD4+CD25+ regulatory T cells that secrete TGFbeta and IL-10 are preferentially induced by a vaccine vector. J Immunother (2004) 1.05
Multiple effector mechanisms induced by recombinant Listeria monocytogenes anticancer immunotherapeutics. Adv Appl Microbiol (2009) 1.04
Prognostic significance of tumor-infiltrating lymphocytes in oropharyngeal cancer. Ear Nose Throat J (2007) 1.02
Listeria monocytogenes as a vector for tumor-associated antigens for cancer immunotherapy. Expert Rev Vaccines (2006) 1.01
Listeria monocytogenes-based antibiotic resistance gene-free antigen delivery system applicable to other bacterial vectors and DNA vaccines. Infect Immun (2004) 1.01
Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine (2008) 1.01
Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine. Arch Otolaryngol Head Neck Surg (2004) 1.00
Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice. Mol Ther (2011) 1.00
The ability of two Listeria monocytogenes vaccines targeting human papillomavirus-16 E7 to induce an antitumor response correlates with myeloid dendritic cell function. J Immunol (2004) 0.98
Development of a Listeria monocytogenes based vaccine against prostate cancer. Cancer Immunol Immunother (2008) 0.98
Rhesus macaques with high levels of vaccine induced IFN-gamma producing cells better control viral set-point following challenge with SIV239. Vaccine (2005) 0.98
In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines. Cancer Immunol Immunother (2006) 0.97
Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment. Bioeng Bugs (2010) 0.97
Vaccination strategy determines the emergence and dominance of CD8+ T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer. Cancer Res (2006) 0.96
DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication. Virology (2005) 0.96
The induction of HIV Gag-specific CD8+ T cells in the spleen and gut-associated lymphoid tissue by parenteral or mucosal immunization with recombinant Listeria monocytogenes HIV Gag. J Immunol (2003) 0.95
Immunoediting sculpts tumor epitopes during immunotherapy. Cancer Res (2007) 0.95
Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors. Immunol Res (2008) 0.94
Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy. Clin Vaccine Immunol (2008) 0.92
Cancer immunotherapy using recombinant Listeria monocytogenes: transition from bench to clinic. Hum Vaccin (2011) 0.91
Live-attenuated Listeria-based immunotherapy. Expert Rev Vaccines (2013) 0.91
Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105. Cancer Immunol Immunother (2011) 0.91
Production of Trametes pubescens laccase under submerged and semi-solid culture conditions on agro-industrial wastes. PLoS One (2013) 0.90
Listeria monocytogenes and its products as agents for cancer immunotherapy. Adv Immunol (2012) 0.90
Enhancing the immunogenicity of bioengineered Listeria monocytogenes by passaging through live animal hosts. Vaccine (2003) 0.89
What is needed for effective antitumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV-associated tumors. Cancer Immunol Immunother (2005) 0.89
Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma. Cancer Immunol Immunother (2007) 0.88
Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer. Cancer Immunol Immunother (2012) 0.88
The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy. Cancer Immunol Immunother (2011) 0.88
Adjuvant properties of listeriolysin O protein in a DNA vaccination strategy. Cancer Immunol Immunother (2006) 0.88
Increased viral load correlates with improved survival in HPV-16-associated tonsil carcinoma patients. Acta Otolaryngol (2008) 0.87
Listeria monocytogenes-derived listeriolysin O has pathogen-associated molecular pattern-like properties independent of its hemolytic ability. Clin Vaccine Immunol (2012) 0.87
Assessment of the ovine acute phase response and hepatic gene expression in response to Escherichia coli endotoxin. Vet Immunol Immunopathol (2006) 0.87
Tumor sensitivity to IFN-gamma is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors. Cancer Immunol Immunother (2004) 0.87
Production of polyclonal antisera. Curr Protoc Neurosci (2009) 0.86
Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome. Curr Mol Med (2009) 0.86
Vaccination with immunotherapeutic Listeria monocytogenes induces IL-17(+) γδ T cells in a murine model for HPV associated cancer. Oncoimmunology (2012) 0.86
Characterization of ovine hepatic gene expression profiles in response to Escherichia coli lipopolysaccharide using a bovine cDNA microarray. BMC Vet Res (2006) 0.84
Improved protection conferred by vaccination with a recombinant vaccinia virus that incorporates a foreign antigen into the extracellular enveloped virion. Virology (2004) 0.84
Vaccination with human papillomavirus type 16 E7 peptide with CpG oligonucleotides for prevention of tumor growth in mice. Arch Otolaryngol Head Neck Surg (2006) 0.84
Molecular analysis of alloreactive CTL post-hemopoietic stem cell transplantation. J Immunol (2007) 0.84
Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunization. Viral Immunol (2009) 0.83
Effects of the tumor microenvironment on the efficacy of tumor immunotherapy. Immunol Invest (2006) 0.81
Interferon γ-induced intratumoral expression of CXCL9 alters the local distribution of T cells following immunotherapy with Listeria monocytogenes. Oncoimmunology (2013) 0.81
Molecular TCR diagnostics can be used to identify shared clonotypes after allogeneic hematopoietic stem cell transplantation. Exp Hematol (2004) 0.81
Effect of a novel DNA vaccine on angiogenesis and tumor growth in vivo. Arch Otolaryngol Head Neck Surg (2010) 0.80
Variation in the ovine cortisol response to systemic bacterial endotoxin challenge is predominantly determined by signalling within the hypothalamic-pituitary-adrenal axis. Toxicol Appl Pharmacol (2008) 0.79
Successful vaccination of immune suppressed recipients using Listeria vector HIV-1 vaccines in helminth infected mice. Vaccine (2013) 0.78
Production of polyclonal antisera. Curr Protoc Cytom (2008) 0.78
Shared and individual specificities of immunodominant cytotoxic T-cell clones in paroxysmal nocturnal hemoglobinuria as determined by molecular analysis. Exp Hematol (2004) 0.78
HIV-1 vaccine-specific responses induced by Listeria vector vaccines are maintained in mice subsequently infected with a model helminth parasite, Schistosoma mansoni. Vaccine (2013) 0.77
Production of polyclonal antisera. Curr Protoc Mol Biol (2008) 0.76
Bone marrow vaccination: a novel approach to enhance antigen specific antitumor immunity. Vaccine (2011) 0.75
When it comes to CTL recognition, size does matter. J Immunol (2006) 0.75
Congenital colonic malformation ("short colon") in a 4-month-old standardbred foal. Can Vet J (2007) 0.75
Diffuse intranasal papillomatosis and its association with human papillomavirus. Arch Otolaryngol Head Neck Surg (2008) 0.75
Hypothermia during head and neck surgery. Laryngoscope (2003) 0.75
Retropharyngeal carotid artery: an important anatomic variation for the anesthesiologist. Anesthesiology (2009) 0.75
Technology evaluation: HspE7 (Stressgen). Curr Opin Mol Ther (2005) 0.75